{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.7","upperLimit":"30.4","value":"25.9"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"8.8","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"411"}],"units":"Participants"}],"description":"ORR is defined as Percentage of participants with a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR=At least a 30% decrease in the sum of diameters of target lesions, the baseline sum diameters used as reference. Tumor assessments began at 8 weeks following randomization and continued every 8 weeks for the first year, then every 12 weeks thereafter until disease progression or death. CIs used Clopper and Pearson.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG001","title":"Everolimus"}],"paramType":"NUMBER","populationDescription":"All randomized participants; any participants that was randomized to any treatment group in the study.","reportingStatus":"POSTED","timeFrame":"from randomization up to disease progression or death (approximately up to 105 Months)","title":"Investigator-assessed Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}